JPMorgan downgrades Medibank stock rating to Neutral despite price target increase

Published 17/07/2025, 11:50
JPMorgan downgrades Medibank stock rating to Neutral despite price target increase

Investing.com - JPMorgan has downgraded Medibank Pvt Ltd. (ASX:MPL) (OTC:MDBPF) from Overweight to Neutral while raising its price target to AUD5.10 from AUD4.80 ahead of the company’s upcoming financial results.

The Australian health insurer is scheduled to release its FY25 results on August 28. JPMorgan believes Medibank has substantial buffers in its underlying management claims assumptions for FY25, which should ensure a strong second-half performance.

Looking beyond the current fiscal year, JPMorgan identified several challenges that prompted the downgrade. These include a lower CY25 rate increase compared to competitors, likely claims cash inflation, and discounting by Medibank to boost volumes in the second half of the year.

The investment bank also noted pressures from Australia’s health minister for higher hospital benefit payout ratios, suggesting that some targets being discussed would be "unachievable for the for-profit sector without sharp profit margin pain."

While Medibank’s FY25 gross margin may increase modestly due to growth in higher-margin non-resident premiums, JPMorgan indicated the company’s previously reported low per-policy inflation of approximately 2.5% is substantially below contracting trends in the market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.